Transcranial Photobiomodulation With Patients With Parkinson's Disease
Posture Stability and Functional Activity Changes After Transcranial Photobiomodulation for Patients With Parkinson's Disease: A Randomized Controlled Trial
1 other identifier
interventional
38
1 country
1
Brief Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive and disabling disease with significative impact on quality of life. Since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. The aim of the study was to see how transcranial photobiomodulation (tPBM) helped patients with Parkinson's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable parkinson-disease
Started Dec 2024
Shorter than P25 for not_applicable parkinson-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 5, 2024
CompletedFirst Posted
Study publicly available on registry
December 11, 2024
CompletedStudy Start
First participant enrolled
December 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 3, 2025
CompletedApril 8, 2025
April 1, 2025
3 months
December 5, 2024
April 6, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
posture stability
The Biodex Balance System (Biodex Medical Systems Inc, USA) Will be used to assess the limit of stability (overall, forward and backward) pre- and post-treatment.
8 weeks
Secondary Outcomes (1)
functional activity
8 weeks
Study Arms (2)
study group
EXPERIMENTALcontrol group
ACTIVE COMPARATORInterventions
Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).
Eligibility Criteria
You may qualify if:
- idiopathic PD,
- Hoehn \& Yahr stage I-IV,
- independent gait with or without technical assistance
- stable parkinsonian medication for at least a month before the study star.
You may not qualify if:
- comorbidities that affect balance or walking,
- other neurological pathologies besides PD,
- chronic diseases not medically controlled and participation in another physiotherapy program or sport activity during the intervention period or in the month before starting the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Al Zaytoonah University
Amaan, Jordan
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- associate professor hanan hosny M Battesha
Study Record Dates
First Submitted
December 5, 2024
First Posted
December 11, 2024
Study Start
December 15, 2024
Primary Completion
March 20, 2025
Study Completion
April 3, 2025
Last Updated
April 8, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share